Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04239573 · ClinicalTrials.gov registry record · NA
Comparing Two Methods to Follow Patients With Pancreatic Cysts
A NA study of Pancreatic Carcinoma, sponsored by ECOG-ACRIN Cancer Research Group.
- Active
- Registry status
- NA
- Development phase
- 4,606
- Enrollment target
- 20
- Study locations
NCT04239573: Active NA study of Pancreatic Carcinoma, sponsored by ECOG-ACRIN Cancer Research Group.
NCT04239573 is a NA study of Pancreatic Carcinoma that is active but no longer recruiting, run by ECOG-ACRIN Cancer Research Group. The registered enrollment target is 4,606 participants, above the 3,229-participant average among 18 other Pancreatic Carcinoma trials with a reported enrollment target (43% higher). The trial reports 20 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04239573, a NA study of Pancreatic Carcinoma, is active but no longer recruiting, sponsored by ECOG-ACRIN Cancer Research Group.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 4,606 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to compare the two approaches for monitoring pancreatic cysts. The study doctors want to compare more frequent monitoring vs less frequent monitoring in order to learn which monitoring method leads to better outcome for patients with pancreatic cysts.
Primary Outcome
Will assess the predictive performance of both primary markers separately. Time to first occurrence of worrisome features and/or high-risk stigmata will be measured from the time of baseline blood draw. Will use an overall significance level of 0.1. Will use a Bonferroni correction for multiplicity adjustment, the significance level applied to both primary biomarkers will be 0.05. Will evaluate using a two-sided log-rank test comparing time to occurrence of worrisome features and/or high-risk st
Conditions Studied
Interventions
- PROCEDURE Computed Tomography
- OTHER Quality-of-Life Assessment
- PROCEDURE Magnetic Resonance Imaging
- OTHER Questionnaire Administration
- PROCEDURE Endoscopic Ultrasound
Study Locations (20)
Alaska
- Anchorage Associates in Radiation Medicine - Anchorage
- Anchorage Radiation Therapy Center - Anchorage
- Alaska Breast Care and Surgery LLC - Anchorage
- Alaska Oncology and Hematology LLC - Anchorage
- Alaska Women's Cancer Care - Anchorage
- Anchorage Oncology Centre - Anchorage
- Katmai Oncology Group - Anchorage
- Providence Alaska Medical Center - Anchorage
California
- Providence Saint Joseph Medical Center/Disney Family Cancer Center - Burbank
- Enloe Medical Center - Chico
- UC San Diego Health System - Encinitas - Encinitas
- UC San Diego Moores Cancer Center - La Jolla
- Loma Linda University Medical Center - Loma Linda
- Veterans Affairs Loma Linda Healthcare System - Loma Linda
- UCLA / Jonsson Comprehensive Cancer Center - Los Angeles
Alabama
- University of Alabama at Birmingham Cancer Center - Birmingham
- University of South Alabama Mitchell Cancer Institute - Mobile
Arizona
- Mayo Clinic Hospital in Arizona - Phoenix
- Mayo Clinic in Arizona - Scottsdale
Arkansas
- University of Arkansas for Medical Sciences - Little Rock
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4,606 participants |
| Start Date | 2020-06-16 |
| Est. Completion | 2037-06-03 |
| Phase | NA |
What the registry record for NCT04239573 still lists
NCT04239573 is an interventional study that assigns participants to a tested intervention. Its 4,606 participants enrollment target places it among the larger protocols in the corpus, above the 3,229-participant average among 18 other Pancreatic Carcinoma trials with a reported enrollment target (43% higher).
The record links to 1 condition, with Pancreatic Carcinoma appearing as the primary indexed condition, and to 5 interventions - of which Computed Tomography is the first listed.
NCT04239573 names 20 study sites across 5 states, led by Alaska, California, Alabama.
Frequently Asked Questions
What is clinical trial NCT04239573 about?
NCT04239573 is a clinical study titled "Comparing Two Methods to Follow Patients With Pancreatic Cysts". The purpose of this study is to compare the two approaches for monitoring pancreatic cysts. The study doctors want to compare more frequent monitoring vs less frequent monitoring in order to learn which monitoring method leads to better outcome for patients with pancreatic cysts.
What is the current status of trial NCT04239573?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 4,606 participants. The study started on 2020-06-16. Estimated completion is 2037-06-03.
What conditions does trial NCT04239573 study?
This clinical trial studies the following conditions: Pancreatic Carcinoma.
What interventions are being tested in trial NCT04239573?
The interventions under investigation include: Computed Tomography (PROCEDURE), Quality-of-Life Assessment (OTHER), Magnetic Resonance Imaging (PROCEDURE), Questionnaire Administration (OTHER), Endoscopic Ultrasound (PROCEDURE).
Who is sponsoring clinical trial NCT04239573?
This trial is sponsored by ECOG-ACRIN Cancer Research Group, which has 75 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04239573 being conducted?
This trial has 20 study locations across Alabama, Alaska, Arizona, Arkansas, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pancreatic Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04239573's enrollment target sits among peer trials
4,606 3rd of 18 higher than 16 of 18 other Pancreatic Carcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pancreatic Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Pilot Comparing ctDNA IDV vs. SPV Sample in Pts Undergoing Biopsies for Hepatobiliary and Pancreatic Cancers
RECRUITING · NA
-
The Vanguard Study: Testing a New Way to Screen for Cancer
RECRUITING · NA
-
HOPE-Genomics Intervention for the Improvement of Cancer Patient Knowledge of Genomics
ACTIVE NOT RECRUITING · NA
-
The RIOT Trial: Re-Defining Frailty and Improving Outcomes With Prehabilitation for Pancreatic, Liver, or Gastric Cancer
COMPLETED · NA
-
Clinical Outcomes for Offering Genetic Testing in a Tiered Approach
COMPLETED · NA
-
Lanreotide Versus Placebo Before Surgery to Prevent a Surgical Complication Called a Pancreatic Fistula
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05768217 · 4,600 participants · NA
Community Resiliency Collective Efficacy Intervention
- NCT06535139 · 4,630 participants · NA
ReMARK: Addressing Disparities in Rural HPV-related Cancer Prevention
- NCT06702878 · 4,514 participants · Phase 3
Light-Activated Antimicrobial Therapy to Prevent Surgical Site Infections
- NCT04371900 · 4,700 participants · NA
Michigan Contraceptive Access, Research, and Evaluation Study Children: Phase 1
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI